Cantor Fitzgerald is “surprised” Humana (HUM) is not trading down further pre-market following the company’s Q3 results. While the results were “clean,” guidance for 2025 was “disappointing,” with initial 2025 guidance set at least in-line with 2024, at $16, well below consensus and inclusive of STARS and efficiency investments, the analyst tells investors in a research note. The firm’s primary concern on this is whether it implies if 2026 STARS are not overturned that Humana believes it would be a multiyear path to fixing as opposed to what CVS (CVS) did with a one-year turnaround. Cantor made no change to its Neutral rating and $395 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana sees FY25 adjusted EPS at least in line with final FY24 results
- Humana sees 2025 PDP membership similar to 2024 at 2M
- Humana committed to achieving individual MA margin target of at least 3%
- Humana Updates 2024 EPS Guidance and Membership Growth
- Humana reports Q3 adjusted EPS $4.16, consensus $3.40